Nintedanib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Nintedanib and local guidelines before prescribing.

Antifibrotic

Mechanism

Tyrosine kinase inhibitor targeting FGFR, PDGFR, VEGFR.

Uses

Idiopathic pulmonary fibrosis, progressive fibrosing ILD, systemic sclerosis ILD.

Dosing

Side effects

Diarrhoea, nausea, raised LFT, weight loss, bleeding risk, thromboembolism.

Interactions

P-gp and CYP3A4 inhibitors or inducers alter levels; anticoagulants.

Contraindications and cautions

Moderate to severe liver impairment, bleeding risk

Monitoring

LFT, weight, GI symptoms

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Avoid in moderate to severe liver impairment

Overdose and reversal

Supportive

Special advice

Take with food; manage diarrhoea early with loperamide; check LFT monthly for first 3 months.

More from the textbook: uses, cautions and other points
Where it is discussed in the book